Bacterial Therapeutics: Addressing the Affordability Gap in Cancer Therapy

IF 12.5 1区医学 Q1 ONCOLOGY

Cancer research Pub Date : 2025-07-15 DOI:10.1158/0008-5472.can-25-0870

Kejsi Prifti, Chiswili Yves Chabu, Koichi S. Kobayashi, Jianxun Song, Arum Han, Paul de Figueiredo

引用次数: 0

Abstract

The global cancer care burden is projected to reach $25 trillion by 2050, with the United States experiencing increasing costs from $57 billion to $209 billion. The application of expensive cellular immunotherapies (exceeding $300,000 per treatment) will exacerbate escalating cancer care costs. Bacteria-based immunotherapies are emerging as safe, lower-cost alternatives. Recent synthetic biology and artificial intelligence advances may enable the development of next-generation bacterial therapies with reduced toxicity. These systems can bypass cold chain constraints and be manufactured at <$10/dose, offering more than 30,000-fold cost savings compared to cell therapies. Therefore, as they evolve, bacterial therapies could transform cancer care by improving outcomes and alleviating global healthcare economic pressures.

查看原文本刊更多论文

细菌疗法：解决癌症治疗的可负担性差距

到2050年，全球癌症治疗负担预计将达到25万亿美元，其中美国的费用将从570亿美元增加到2090亿美元。昂贵的细胞免疫疗法（每次治疗超过30万美元）的应用将加剧不断上升的癌症护理费用。基于细菌的免疫疗法正在成为安全、低成本的替代疗法。最近合成生物学和人工智能的进步可能使下一代毒性降低的细菌疗法的发展成为可能。这些系统可以绕过冷链限制，制造成本为10美元/剂，与细胞疗法相比，节省了3万多倍的成本。因此，随着它们的发展，细菌疗法可以通过改善结果和减轻全球医疗保健经济压力来改变癌症治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer research 医学-肿瘤学

CiteScore

16.10

自引率

0.90%

发文量

7677

审稿时长

2.5 months

期刊介绍： Cancer Research, published by the American Association for Cancer Research (AACR), is a journal that focuses on impactful original studies, reviews, and opinion pieces relevant to the broad cancer research community. Manuscripts that present conceptual or technological advances leading to insights into cancer biology are particularly sought after. The journal also places emphasis on convergence science, which involves bridging multiple distinct areas of cancer research. With primary subsections including Cancer Biology, Cancer Immunology, Cancer Metabolism and Molecular Mechanisms, Translational Cancer Biology, Cancer Landscapes, and Convergence Science, Cancer Research has a comprehensive scope. It is published twice a month and has one volume per year, with a print ISSN of 0008-5472 and an online ISSN of 1538-7445. Cancer Research is abstracted and/or indexed in various databases and platforms, including BIOSIS Previews (R) Database, MEDLINE, Current Contents/Life Sciences, Current Contents/Clinical Medicine, Science Citation Index, Scopus, and Web of Science.